{"id":"https://genegraph.clinicalgenome.org/r/5fa5cb9c-70c0-4408-b4da-0dfe65d12a61v1.0","type":"EvidenceStrengthAssertion","dc:description":"ALPL has been described in association with autosomal dominant mild hypophosphatasia (Taillandier et al., 2018; PMID:29236161). Mild hypophosphatasia is the most common form of hypophosphatasia characterized by low serum alkaline phosphatase, nonspecific clinical signs, and typically presents in individuals in adulthood. This condition can and has been reported to progress to more severe forms in patients. Based upon the severity and mode of inheritance of the hypophosphatasia clinical subtypes, the curations for autosomal recessive severe hypophosphatasia, autosomal recessive moderate hypophosphatasia, and autosomal dominant moderate hypophosphatasia have been split and curated separately (PMID: 32973344). Twelve variants (missense, frameshift, splice, nonsense) that have been reported in twelve probands in 3 publications (PMIDs: 29236161, 30864637, 33191482) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is reported to be loss of function. This gene-disease association is also supported by an mRNA expression study (GTEx, Illumina, BioGPS, and SAGE; https://www.genecards.org/cgi-bin/carddisp.pl?gene=ALPL&keywords=alpl#expression). In summary, ALPL is definitively associated with autosomal dominant mild hypophosphatasia. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This curation was approved by the ClinGen Skeletal Disorders Gene Curation Expert Panel on 5/19/21 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5fa5cb9c-70c0-4408-b4da-0dfe65d12a61","GCISnapshot":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10065","date":"2021-05-19T07:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10065","date":"2021-06-12T00:34:39.497Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_ad_null_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/161c92d4-341b-49d0-a68b-4c0021a9d03e_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c83c7023-eb59-48d8-8731-4bb8e73f8d30","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 56","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":64,"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"ALPL levels 92% of lower limit of normal range","phenotypes":"obo:HP_0002757","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/161c92d4-341b-49d0-a68b-4c0021a9d03e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/2c4a63a6-6034-4111-8d4f-8765fb44b94b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.997+2T>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA338880452"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9dd709db-44b1-4da1-9224-544d8ec6c499_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0788b0a-68de-4831-add5-4340b00c2046","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30864637","rdfs:label":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":41,"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Denied history of fractures, teeth loss, cavities, muscle pain, ID, or vitamin supplementation\nFamily history of premenopausal osteoporosis with poor response to bisphosphonates and fractures\nOn physical exam, slight lack of enamel seen in teeth\nDecreased ALP levels for last 2 years seen and high vitamin B6 levels seen\nNo radiographic abnormalities reported","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9dd709db-44b1-4da1-9224-544d8ec6c499_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30864637","allele":{"id":"https://genegraph.clinicalgenome.org/r/b2374966-cf2d-46d1-a3ab-331529e8384f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1474del (p.Ala492fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/632630"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9b4d6ee6-90a8-49d8-b297-bb52e03bf775_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/483ee97c-e6ee-4d5a-bb1b-72de6db05f6a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 55","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":38,"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"ALPL levels 80% of lower limit of normal range","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9b4d6ee6-90a8-49d8-b297-bb52e03bf775_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/b4f96f7c-3f63-4ade-b934-3169cfa21431","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.809G>A (p.Trp270Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA274277"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/56a63f87-2648-455d-ba67-ce4557ae3448_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22204ebb-356b-46ea-b54a-bc691a06b57f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","rdfs:label":"Patient 17","ageType":"AgeAtReport","ageUnit":"Years","ageValue":69,"firstTestingMethod":"PCR","phenotypeFreeText":"Low BMD, bone marrow edema proximal tibia, cephalgia, arthralgia, myalgia, reduced grip force","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/56a63f87-2648-455d-ba67-ce4557ae3448_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","allele":{"id":"https://genegraph.clinicalgenome.org/r/7e9597b9-1748-4b04-939a-119076777cf9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1558_1559del (p.Leu520fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658656892"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/343ebd86-f775-4c3b-a2e6-d99773920507_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18681ade-8c96-4355-84e2-89c730cfc5ee","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 54","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":55,"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"ALPL levels 82% of lower limit of normal range","phenotypes":"obo:HP_0002757","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/343ebd86-f775-4c3b-a2e6-d99773920507_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/f9873913-5494-475d-b267-bb61ee344696","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.187_205del (p.Gly63LeufsTer53)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139771350"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/14a3b3eb-f478-41e1-9e76-df599a9dc53e_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91e4ce93-1cb8-400d-9e91-2815f908d524","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","rdfs:label":"Patient 15","ageType":"AgeAtReport","ageUnit":"Years","ageValue":58,"firstTestingMethod":"PCR","phenotypeFreeText":"Adult HPP was diagnosed, if ALP or BAP activity was repeatedly below the reference range or around the lower limit value together with elevated PLP, bone complications and at least one further complication concerning teeth, muscle, central nervous and mental system supported by at least one rare ALPL variant\n\nPseudarthrosis, tooth hypomineralization, migraine, myalgia, tendinosis calcarea, reduced grip force\n\nDecreased ALP levels: 20 U/L, BAP (bone specific ALP): 1.9 U/L, Elevated PLP (Pyridoxal 5’-phosphate): 37.4 μg/L ","phenotypes":["obo:HP_0003326","obo:HP_0002076","obo:HP_0005864"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/14a3b3eb-f478-41e1-9e76-df599a9dc53e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","allele":{"id":"https://genegraph.clinicalgenome.org/r/fc0be730-0b1a-4581-a15a-919467ac4352","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1171dup (p.Arg391fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA666743"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":9},{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_ad_other_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0393d3c1-f9a2-4503-a44e-26419d35b61b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Dominant negative effect ruled out - 37.1% of WT activity \n(Fauvert 2009)\n","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf38a0e5-3f54-418f-9b83-cf808c490159","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 32","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":34,"firstTestingMethod":"Next generation sequencing panels","phenotypes":"obo:HP_0002757","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0393d3c1-f9a2-4503-a44e-26419d35b61b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/efbae290-60fb-4da5-beb9-7b338fcc7f83","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1468A>T (p.Ile490Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA338882313"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d6ea63ed-07c1-4366-95c1-ac0d4f64f586_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Dominant negative effect ruled out - 7.2% of WT activity \n(Del Angel 2020)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/985d8c6f-2230-404e-8a14-0380955033f2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 17","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":55,"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"ALPL levels 40% of lower limit of normal range, history of bisphosphonate treatment","phenotypes":"obo:HP_0002757","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d6ea63ed-07c1-4366-95c1-ac0d4f64f586_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/fab9d125-5610-4e6d-b9c8-a867695403a0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1328C>T (p.Ala443Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA338881972"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c2c52144-1468-4db5-a4ba-abb9729faee7_proband_score_evidence_line","type":"EvidenceLine","dc:description":"21.4% of WT activity \n(Del Angel 2020)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ae583d27-6513-4c4a-9212-e0f648888365","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 33","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":46,"phenotypeFreeText":"ALPL levels 71% of lower limit of normal range, history of bisphosphonate treatment","phenotypes":"obo:HP_0002757","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c2c52144-1468-4db5-a4ba-abb9729faee7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/4b3bb769-61e5-4d9a-9028-522939781f51","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.571G>A (p.Glu191Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256927"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e0fa51e5-3cea-4200-b64f-16f81882953a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"4.9% activity compared to WT\n(Del Angel 2020)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/745980de-c085-4790-afa2-fd54598e6076","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","rdfs:label":"Patient 13","ageType":"AgeAtReport","ageUnit":"Years","ageValue":57,"firstTestingMethod":"PCR","phenotypeFreeText":"tendinosis calcarea, reduced grip force\n\nDecreased ALP levels: 23 U/L, BAP (bone specific ALP): 4.2 U/L, Elevated PLP (Pyridoxal 5’-phosphate): 39.6 μg/L \n","phenotypes":["obo:HP_0004349","obo:HP_0003326"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e0fa51e5-3cea-4200-b64f-16f81882953a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","allele":{"id":"https://genegraph.clinicalgenome.org/r/626285f6-b0fc-4a8d-b18f-655994b6cb74","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1023T>A (p.His341Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA338881022"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/68a2356e-1eb6-45e8-a03e-e6c3a04ee140_proband_score_evidence_line","type":"EvidenceLine","dc:description":"6.02% activity compared to WT \n(Del Angel 2020)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7e705b0-2083-4295-b51b-30bda75a607a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","rdfs:label":"Patient 12","ageType":"AgeAtReport","ageUnit":"Years","ageValue":49,"firstTestingMethod":"PCR","phenotypeFreeText":"Stress fractures, periodontitis, cephalgia, depression, myalgia, fatigue, reduced grip force\n\nDecreased ALP levels: 25 U/L, BAP (bone specific ALP): 4.5 U/L, Elevated PLP (Pyridoxal 5’-phosphate): 49.4 μg/L ","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/68a2356e-1eb6-45e8-a03e-e6c3a04ee140_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33191482","allele":{"id":"https://genegraph.clinicalgenome.org/r/58fd101f-3e0b-42c3-90d7-483d760c6db9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1004G>C (p.Arg335Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16603569"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6f84c591-d737-49f1-a495-ffe7b05dad92_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afe29e67-8a46-46f7-a646-9d50df6afa49","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","rdfs:label":"Patient 12","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":16,"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"All patients presented various features ranging from recurrent fractures and bone fragility to mild and non-pathognomonic symptoms such as musculoskeletal pain, diffuse pain, osteomalacia and osteopenia or symptoms resembling osteoporosis, calcifications and chondrocalcinosis (specific patient phenotypes not provided)","phenotypes":"obo:HP_0002757","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6f84c591-d737-49f1-a495-ffe7b05dad92_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29236161","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c2e254e-5d98-4209-8ac0-3dd8b22bcf3f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000478.6(ALPL):c.1171C>T (p.Arg391Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA666747"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03912003-38e1-45cc-a005-099e00dd3eec_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9195fb74-4e5e-4e6d-af43-5c769d727e4b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e0c6d67-bb9c-4348-aa9f-1217c5ce1589","type":"Finding","dc:description":"mRNA data shows expression in whole blood, marrow, and bone","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23715323","rdfs:label":"mRNA expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5}],"evidenceStrength":"Definitive","sequence":2903,"specifiedBy":"GeneValidityCriteria8","strengthScore":12.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/qdUojcwSOC4","type":"GeneValidityProposition","disease":"obo:MONDO_0007798","gene":"hgnc:438","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_03912003-38e1-45cc-a005-099e00dd3eec-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}